Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).
Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).
Transcript
What are your thoughts on tissue- vs blood-based biomarker testing and where that area is heading in NSCLC?
Historically, the standard has kind of been tissue-based testing, although I do not think that's the current standard. I think that we have demonstrated the clinical utility of plasma-based testing, which is so much more efficient with regard to next-generation sequencing, because all you have to do is draw the patient's blood. We do it right in the office at the time of their visit, for the first time. And I think we've demonstrated that tissue in plasma-based testing is really complementary. Most of the time, let's say, 80% of the time, you'll find the same thing in tissue that you'll find in blood, but there's about a 20% chance that you'll find something in tissue you don't find in blood, or vice versa, you find something in blood you don't find in tissue.
The other issue with tissue in non–small-cell lung cancer is it's a scarce commodity. Often, our biopsies are not very robust. We actually reviewed a case this morning in our tumor board in which the sample from the tissue biopsy was insufficient for molecular testing. So that's one example. And that's not a terribly uncommon situation in non–small-cell lung cancer because of the nature of the population. And you don't always get a great biopsy. So that's where plasma-based testing can be complementary and should be considered a standard, as well as in conjunction with tissue.
I mentioned clinical utility—I think it's important for people to be aware of the NILE trial where they really looked at the addition of plasma-based testing to tissue-based testing, and it did increase the yield of identifying genomic alterations that had FDA-approved targeted therapies associated with them. So as a part of practice, I find it completely useful. I tend to do both tissue and blood at the time of diagnosis because I think one of the greatest things an oncologist can do for a lung cancer patient is find the genomic driver, because we have these wonderful targeted therapies that are highly effective. And one can't use them unless you make the genomic diagnosis.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More